Protagenic (NASDAQ: PTIX) raises $1.5 million upfront to move anxiety drug toward U.S. trial

What happened

Protagenic Therapeutics, Inc. (NASDAQ: PTIX) received $1.5 million in gross proceeds at the Nov. 17 initial closing of a private placement. The company expects the money to fund IND-enabling work and the start of a Phase 1/2a trial of PT00114, its lead drug, in generalized anxiety disorder.

Investors bought 2,459,014 shares at $0.61 each. That price is 90% of the volume weighted average price over the prior 30 trading days. The deal also issued Series A warrants exercisable at $0.67 and Series B warrants at $0.73, each covering up to the same number of shares.

The company says up to $3.5 million more could come if both warrant series are exercised in full. Total potential gross proceeds would then reach up to $5 million before fees. The purchase agreement sets a maximum offering of $3 million, which the company can raise to the same ceiling at its discretion. More closings are allowed through Dec. 31.

Key numbers

Metric Latest Change Source
Upfront gross proceeds at initial closing $1.5 million SEC 8-K
Additional proceeds if both warrant series are exercised in full up to $3.5 million SEC 8-K, Exhibit 99.1 press release
Total potential gross proceeds up to $5 million SEC 8-K, Exhibit 99.1 press release
Purchase price per share $0.61 SEC 8-K
Series A warrant exercise price $0.67 SEC 8-K
Series B warrant exercise price $0.73 SEC 8-K

Read more: Protagenic Therapeutics (PTIX) company research

Why it matters

Only part of the planned capital is secured. The money in hand is the only portion that does not depend on warrant exercise or extra closings. Placement agent Brookline Capital Markets is due a 7.0% cash fee plus a 1.0% expense allowance on gross proceeds, so net proceeds will be lower.

OptimistFi has described PTIX as a financing- and evidence-dependent biotech option. This raise pays for a route into the U.S. clinic. It also adds shares and warrants, and it does not validate PT00114. In August, the FDA's written responses identified no deficiencies that would preclude an IND submission.

President Bill Nichols Jr. said the company expects the financing to carry it to enrollment of its first patients. He believes that will be a value inflection point. The company's own risk list includes its ability to continue as a going concern. It also says FDA pre-IND advice is non-binding and the agency could ask for more information or impose a clinical hold.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The company targets an IND submission in late Q1 2027 and first patient dosing in Q2 2027, subject to FDA review of the IND. An on-time filing would support the plan to use these proceeds for the trial. A delay or clinical hold would weaken it. Topline safety data are expected in the second half of 2027. The company has also agreed to file a resale registration statement within 45 days.

More from OptimistFi

From OptimistFi Perps

Sources

Explore OptimistFi research on Protagenic Therapeutics, Inc.: https://optimistfi.com/stocks/PTIX

Browse Protagenic Therapeutics, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

Find available research on the Protagenic Therapeutics, Inc. company page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.